In this video, Prof. Dr. Ivan Borbath (Cliniques Universitaires Saint-Luc, Brussels) discusses the results of the HIMALAYA trial, underscoring the place of dual immunotherapy with durvalumab and tremelimumab in the frontline treatment of advanced hepatocellular carcinoma.
NS ID XL-3367-Revision date 04/2023-LB